Alterations of the Notch pathway in lung cancer

The pathological significance of Notch1 in oral squamous cell carcinoma

“…Although the oncogenic role of Notch signaling in T-ALL is well established, 32 a common theme for the role of Notch signaling in tumorigenesis remains elusive. In many types of solid tumor, including cancers of the lung, 11 breast, 16 pancreas 13 and prostate. 14 Notch1 signaling therefore seems to have a crucial role.…”

“…10 The dysregulated expression of Notch receptors, ligands and targets is also observed in solid tumors, including lung, pancreatic, cervical and prostate carcinomas. [11][12][13][14] High-level expressions of Notch1 and JAG1 are associated with poor prognoses in patients with breast cancer or metastasis of prostate cancer. 15,16 On the other hand, there is growing evidence that Notch signaling activation may have growthsuppressive functions in other hematopoietic cells, hepatocytes, the pancreatic epithelium and skin.…”

Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer

“…Interestingly, Notch signaling previously has been reported to function as both a tumor suppressor and an oncogene (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32). The dependency of Notch1 function in cancer may be tissue specific and context dependent (21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32). Loss-offunction mutations in Notch receptors support their tumor-suppressive role in multiple malignances, including bladder cancer and squamous cell carcinoma (22)(23)(24).…”

“…Constitutive activation of the Notch receptors through gene rearrangements or mutations leads to Notch receptors' oncogenic function in 55-60% of patients with T-cell acute lymphoblastic leukemia (26,27). An oncogenic role of Notch1 also has been demonstrated in chronic lymphocytic leukemia and in solid tumors such as lung adenocarcinoma and others (28)(29)(30)(31). Mutations within Notch1 receptor are rare (3% frequency) in metastatic prostate cancer (32,33).…”

Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines

“…Clinical data have demonstrated that 30% of NSCLC cases have increased Notch-1 activity, whereas 10% have a gain-offunction mutation in the NOTCH-1 gene (7). After a series of proteolytic cleavages, the active form of Notch-1 translocates from the cell membrane into the nucleus and subsequently regulates the expression of target genes, such as CCND1, Bcl-2, and Survivin (8 -10).…”